• Ruxolitinib Induces Apoptosis and Pyroptosis in Anaplastic T

  2026-06-03

  This study uncovers how Ruxolitinib phosphate (INCB018424), a selective JAK1/2 inhibitor, triggers apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma (ATC) by blocking DRP1-mediated mitochondrial fission. These findings provide a new mechanistic rationale for targeting the JAK/STAT pathway in aggressive thyroid malignancies and highlight potential research avenues in mitochondrial dynamics and cell death modalities.

• Phenacetin as a Gold-Standard Probe in Translational Drug Re

  2026-06-03

  Explore how Phenacetin (N-(4-ethoxyphenyl)acetamide) bridges mechanistic insight and practical workflow in advanced pharmacokinetic research. This article analyzes its molecular rationale, validation in organoid systems, nephropathy risks, and the strategic implications for translational scientists seeking reproducibility and regulatory foresight.

• Estradiol–Autophagy Axis: Multi-Organ Protection in Perimeno

  2026-06-02

  This study uncovers how declining estradiol levels during perimenopause elevate cardiometabolic and renal risk by disrupting estrogen receptor–mediated autophagy. Integrating human cohort analysis, network pharmacology, and mouse models, it clarifies receptor-specific mechanisms of organ protection, offering mechanistic guidance for precision hormone therapy research.

• Dinaciclib (SCH727965): Redefining Cell Cycle Control for Tr

  2026-06-02

  This thought-leadership article explores how Dinaciclib (SCH727965) enables translational researchers to dissect the mechanistic interplay between cell cycle regulation, apoptosis, and tissue boundary maintenance. Integrating recent developmental biology findings with actionable protocol guidance, we chart a visionary path forward for oncology and mechanobiology studies using multi-CDK inhibitors.

• Ribociclib Succinate (LEE011): Precision CDK Inhibition in C

  2026-06-01

  Explore how Ribociclib succinate (LEE011 succinate) advances cancer research as a potent CDK inhibitor by offering unique mechanistic insights, superior solubility, and practical assay guidance. This article reveals nuanced protocol parameters and differentiates its approach from existing workflow-centric resources.

• Spiroplasma eriocheiris Cell Entry: Endocytic Pathways Revea

  2026-06-01

  Wei et al. provide the first direct evidence that Spiroplasma eriocheiris invades Drosophila S2 cells using clathrin-mediated endocytosis and macropinocytosis, but not caveola-dependent routes. Their integrative model system and pathway dissection offer new tools for understanding host-pathogen interactions in invertebrates and inform cell biological approaches in related infection studies.

• Epigenetic Regulator Inhibition Shapes Immune Signatures in

  2026-05-31

  Anichini et al. systematically compared immune-related gene expression changes induced by various epigenetic drugs in melanoma cell lines. Their findings highlight the distinct and robust immunomodulatory activity of guadecitabine, providing a rationale for its integration with immunotherapy strategies.

• Angiotensin II in Cardiac Remodeling: New Insights for Advan

  2026-05-30

  Explore the multifaceted role of Angiotensin II in cardiac remodeling and heart failure pathogenesis. This article offers a deep scientific perspective on Angiotensin II, supported by recent breakthroughs, to empower cutting-edge vascular and hypertrophy research.

• TP53 and DNA Damage Sensing Govern Calicheamicin ADC Efficac

  2026-05-29

  This study employs genome-wide CRISPR/Cas9 screening to reveal that TP53 and other DNA damage response regulators critically modulate sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) in acute leukemia. The findings inform rational design of combination therapies and highlight the importance of DNA repair pathways in therapeutic resistance.

• CHIR-99021 (CT99021): Beyond Pluripotency—A Systems Approach

  2026-05-29

  Explore the multi-layered role of CHIR-99021 (CT99021) in stem cell signaling, with new insights into WNT-GSK3 interactions and advanced applications in differentiation and cell fate. This article uniquely bridges molecular mechanism to assay design for next-generation stem cell research.

• Disrupting SARS-CoV-2 Nucleocapsid Condensation to Inhibit R

  2026-05-28

  Zhao et al. identify that SARS-CoV-2 nucleocapsid protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process essential for viral replication and assembly. Their work demonstrates that (-)-gallocatechin gallate (GCG) disrupts this condensate formation, offering a mechanistic foundation for targeting LLPS in antiviral strategies.

• 2-Deoxy-D-glucose: Metabolic Modulation, Cytoskeleton, and C

  2026-05-28

  Explore how 2-Deoxy-D-glucose (2-DG) uniquely links glycolysis inhibition to cytoskeletal regulation and cancer metabolism. This in-depth review integrates recent breakthroughs in metabolic regulation and provides advanced guidance for assay design.

• Anagliptin (SK-0403): Beyond Glycemic Control in Vascular Re

  2026-05-27

  Explore how Anagliptin (SK-0403) advances research on diabetes and vascular physiology. This article uncovers unique mechanistic insights and practical protocols for DPP-4 inhibitor applications in metabolic and cardiovascular studies.

• WZ4003: Selective NUAK1/2 Inhibitor for Cancer and Neurodege

  2026-05-27

  WZ4003 is a highly selective NUAK1/2 inhibitor that disrupts cell migration and proliferation by targeting kinase-mediated phosphorylation events. Its use has been validated in both cancer cell assays and Alzheimer’s disease models, providing a robust tool for mechanistic studies. APExBIO supplies WZ4003 (SKU B1374) as a research-grade compound for advanced cellular and ex vivo applications.

• Hexetidine (NSC-17764): Antimicrobial Science & Oral Use Ben

  2026-05-26

  Hexetidine (NSC-17764) is a broad-spectrum antimicrobial agent extensively validated for oral infection control. Its efficacy spans Gram-positive and Gram-negative bacteria and Candida albicans, with application-specific concentrations and clinical protocols supported by peer-reviewed evidence. This article details mechanism, benchmarks, and workflow considerations for biomedical and dental research.

7900 records 10/527 page Previous Next First page 上5页 678910 下5页 Last page